• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The journal of clinical psychiatry >Treatment of depression and menopause-related symptoms with the serotonin-norepinephrine reuptake inhibitor duloxetine.
【24h】

Treatment of depression and menopause-related symptoms with the serotonin-norepinephrine reuptake inhibitor duloxetine.

机译：使用5-羟色胺-去甲肾上腺素再摄取抑制剂度洛西汀治疗抑郁症和更年期相关症状。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: Postmenopausal women with depression frequently have co-occurring symptoms of hot flashes (vasomotor symptoms), sleep disturbance, anxiety, and pain. Treatment strategies that target all of these symptoms together have not been investigated to date. METHOD: Study participants were postmenopausal women, 40 to 60 years old, with major depressive disorder (DSM-IV criteria) and vasomotor symptoms. The study design included a 2-week, single-blind placebo run-in phase followed by an 8-week open-label flexible-dosing (60-120 mg per day) study of duloxetine for women who did not respond to placebo. The primary outcome measure was change in Montgomery-Asberg Depression Rating Scale (MADRS) score during 8 weeks of duloxetine therapy. Secondary outcome measures included changes in vasomotor symptoms, sleep quality, anxiety, and pain. Analyses were conducted using non-parametric methods. Patients were enrolled in the study from May 31, 2005, through May 22, 2006. RESULTS: Of 30 women eligible to participate in this study, 20 initiated treatment with open-label duloxetine. Fourteen (70.0%) of these women completed the study. There was a statistically significant decrease in MADRS scores after 8 weeks of treatment (p < .001), with scores declining from 19.0 (interquartile range [IQR] = 15.0-21.0) to 5.5 (IQR = 3.0-9.0). There was also a statistically significant improvement in vasomotor symptoms (p = .003), anxiety (p = .002), sleep quality (p < .001), and pain (p < .05). CONCLUSIONS: Postmenopausal women with depression and vasomotor symptoms had significant improvement in depression, vasomotor symptoms, sleep, anxiety, and pain after 8 weeks of open-label duloxetine therapy. Given the common co-occurrence of these symptoms in postmenopausal women, duloxetine may offer important therapeutic benefits for postmenopausal women who have depression and menopause-related symptoms.
机译：背景：绝经后抑郁的妇女经常出现潮热（血管舒缩症状），睡眠障碍，焦虑和疼痛的并发症状。迄今尚未研究针对所有这些症状的治疗策略。方法：研究对象为40至60岁的绝经后妇女，患有重度抑郁症（DSM-IV标准）和血管舒缩症状。该研究设计包括为期2周，单盲安慰剂的磨合期，然后是对安慰剂无反应的妇女进行度洛西汀8周开放标签柔性给药（每天60-120 mg）研究。主要结果指标是度洛西汀治疗8周期间蒙哥马利-阿斯伯格抑郁量表（MADRS）得分的变化。次要结果指标包括血管舒缩症状，睡眠质量，焦虑和疼痛的变化。使用非参数方法进行分析。自2005年5月31日至2006年5月22日，患者参加了该研究。结果：在30名符合条件的妇女中，有20名开始使用开放标签度洛西汀治疗。这些妇女中有十四名（70.0％）完成了研究。治疗8周后，MADRS得分有统计学意义的下降（p <.001），得分从19.0（四分位间距[IQR] = 15.0-21.0）下降到5.5（IQR = 3.0-9.0）。血管舒缩症状（p = .003），焦虑症（p = .002），睡眠质量（p <.001）和疼痛（p <.05）也有统计学上的显着改善。结论：绝经后抑郁和血管舒缩症状的妇女在开放标签度洛西汀治疗8周后，抑郁，血管舒缩症状，睡眠，焦虑和疼痛有明显改善。鉴于这些症状在绝经后妇女中普遍存在，因此度洛西汀对患有抑郁症和与更年期相关症状的绝经后妇女可能提供重要的治疗益处。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号